Epstein Secrets

d wounded 22 others." According to the OCR, "The ruling by U.S. District Court Judge Jesus G. Bernal in Riverside could mean a 19-year difference in Marquez's prison term. Marquez, 28, pleaded guilty in February 2017, but his sentencing has been delayed by attorney motions and Marquez's unsuccessful att

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

wounded 22 others." According to the OCR, "The ruling by U.S. District Court Judge Jesus G. Bernal in Riverside could mean a 19-year difference in Marquez's prison term. Marquez, 28, pleaded guilty in February 2017, but his sentencing has been delayed by attorney motions and Marquez's unsuccessful atte

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

d wounded 22 others." According to the OCR, "The ruling by U.S. District Court Judge Jesus G. Bernal in Riverside could mean a 19-year difference in Marquez's prison term. Marquez, 28, pleaded guilty in February 2017, but his sentencing has been delayed by attorney motions and Marquez's unsuccessful att

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug